ZNF335: A Potential Drug Target and Biomarker for Neurological Disorders
ZNF335: A Potential Drug Target and Biomarker for Neurological Disorders
ZNF335 (NIF-1), a gene that encodes for a protein known as NIF-1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF335 is a key regulator of neural development and function, and its dysfunction has been implicated in the development and progression of these diseases.
The NIF-1 protein is involved in a variety of cellular processes that are critical for normal neural development and function. It plays a role in the development and maintenance of neural stem cells, and is also involved in the regulation of neural cell death, plasticity, and regeneration. ZNF335 has been shown to be highly expressed in a variety of neural tissues, including brain, spinal cord, and retina, and has been implicated in the development and progression of various neurological and psychiatric disorders.
One of the most significant findings related to ZNF335 is its involvement in the development of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells, and are some of the most common causes of dementia and cognitive impairment. ZNF335 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and studies have suggested that its dysfunction may contribute to the development and progression of this disease.
In addition to its involvement in neurodegenerative diseases, ZNF335 has also been implicated in the development and progression of other disorders, including cancer and autoimmune diseases. For example, ZNF335 has been shown to be expressed in the tissues of individuals with multiple sclerosis, an autoimmune disorder that characterized by the progressive loss of brain cells. Additionally, ZNF335 has been implicated in the development of certain cancers, such as neuroblastoma, a type of cancer that typically affects children.
The potential utility of ZNF335 as a drug target or biomarker is due to its involvement in a wide range of cellular processes that are critical for normal cellular function and development. Its dysfunction has been implicated in the development and progression of a variety of disorders, including those listed above. As such, ZNF335 may be a valuable target for the development of new treatments for these disorders.
In addition to its potential as a drug target or biomarker, ZNF335 also has important implications for our understanding of normal neural development and function. Its dysfunction has been implicated in the development of various neurological disorders, including those listed above. This suggests that ZNF335 plays a critical role in the development and maintenance of normal neural function, and that its dysfunction may contribute to the development of these disorders.
Overall, ZNF335 is a gene that has significant implications for our understanding of normal cellular function and development, as well as the development and progression of various disorders. Its dysfunction has been implicated in the development and progression of a wide range of conditions, including those listed above. As such, ZNF335 may be a valuable target for the development of new treatments for these disorders, as well as a useful biomarker for the evaluation of these conditions.
Protein Name: Zinc Finger Protein 335
Functions: Component or associated component of some histone methyltransferase complexes may regulate transcription through recruitment of those complexes on gene promoters (PubMed:19131338, PubMed:23178126). Enhances ligand-dependent transcriptional activation by nuclear hormone receptors (PubMed:12215545, PubMed:18180299, PubMed:19131338). Plays an important role in neural progenitor cell proliferation and self-renewal through the regulation of specific genes involved brain development, including REST (PubMed:23178126). Also controls the expression of genes involved in somatic development and regulates, for instance, lymphoblast proliferation (PubMed:23178126)
The "ZNF335 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF335 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488
